-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Advaxis (NASDAQ:ADXS) & Milestone Pharmaceuticals (NASDAQ:MIST) Financial Survey
Advaxis (NASDAQ:ADXS) & Milestone Pharmaceuticals (NASDAQ:MIST) Financial Survey
Advaxis (NASDAQ:ADXS – Get Rating) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.
Earnings & Valuation
This table compares Advaxis and Milestone Pharmaceuticals' revenue, earnings per share and valuation.
Get Advaxis alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Advaxis | $3.24 million | 2.07 | -$17.86 million | ($6.70) | -0.55 |
Milestone Pharmaceuticals | $15.00 million | 15.51 | -$42.85 million | ($1.46) | -5.31 |
Advaxis has higher earnings, but lower revenue than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Advaxis and Milestone Pharmaceuticals, as reported by MarketBeat.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Advaxis | 0 | 0 | 0 | 0 | N/A |
Milestone Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
Milestone Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 29.03%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Advaxis.
Profitability
This table compares Advaxis and Milestone Pharmaceuticals' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Advaxis | N/A | -39.23% | -33.85% |
Milestone Pharmaceuticals | N/A | -57.80% | -54.81% |
Institutional and Insider Ownership
0.1% of Advaxis shares are owned by institutional investors. Comparatively, 67.7% of Milestone Pharmaceuticals shares are owned by institutional investors. 0.3% of Advaxis shares are owned by insiders. Comparatively, 5.6% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Advaxis has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500.
Summary
Milestone Pharmaceuticals beats Advaxis on 8 of the 12 factors compared between the two stocks.
About Advaxis
(Get Rating)
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
About Milestone Pharmaceuticals
(Get Rating)
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
Advaxis (NASDAQ:ADXS – Get Rating) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.
安进(纳斯达克:ADXS-GET评级)和里程碑制药(纳斯达克:MIST-GET评级)都是小盘医疗公司,但哪只是优势股?我们将根据这两家公司的估值、风险、收益、机构所有权、盈利能力、分析师建议和股息的实力进行比较。
Earnings & Valuation
收益与估值
This table compares Advaxis and Milestone Pharmaceuticals' revenue, earnings per share and valuation.
这张表格比较了Advaxis制药公司和迈尔斯顿制药公司的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Advaxis | $3.24 million | 2.07 | -$17.86 million | ($6.70) | -0.55 |
Milestone Pharmaceuticals | $15.00 million | 15.51 | -$42.85 million | ($1.46) | -5.31 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
前进轴 | 324万美元 | 2.07 | -1,786万元 | ($6.70) | -0.55 |
里程碑制药公司 | 1,500万美元 | 15.51 | -4,285万元 | ($1.46) | -5.31 |
Advaxis has higher earnings, but lower revenue than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.
Advaxis的收益高于里程碑制药公司,但营收低于里程碑制药公司。Milmark PharmPharmticals的市盈率低于Advaxis,表明它目前是两只股票中更负担得起的一只。
Analyst Recommendations
分析师建议
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Advaxis | 0 | 0 | 0 | 0 | N/A |
Milestone Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
前进轴 | 0 | 0 | 0 | 0 | 不适用 |
里程碑制药公司 | 0 | 0 | 2 | 0 | 3.00 |
Milestone Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 29.03%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Advaxis.
里程碑制药的共识目标价为10.00美元,表明潜在上涨29.03%。考虑到迈尔斯顿制药公司可能上涨的可能性更高,分析师显然认为迈尔斯顿制药公司比Advaxis更有利。
Profitability
盈利能力
This table compares Advaxis and Milestone Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了Advaxis制药公司和里程碑制药公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Advaxis | N/A | -39.23% | -33.85% |
Milestone Pharmaceuticals | N/A | -57.80% | -54.81% |
净利润率 | 股本回报率 | 资产回报率 | |
前进轴 | 不适用 | -39.23% | -33.85% |
里程碑制药公司 | 不适用 | -57.80% | -54.81% |
Institutional and Insider Ownership
机构和内部人持股
0.1% of Advaxis shares are owned by institutional investors. Comparatively, 67.7% of Milestone Pharmaceuticals shares are owned by institutional investors. 0.3% of Advaxis shares are owned by insiders. Comparatively, 5.6% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Advaxis 0.1%的股份由机构投资者持有。相比之下,里程碑制药67.7%的股份由机构投资者持有。Advaxis 0.3%的股份由内部人士持有。相比之下,里程碑制药5.6%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、捐赠基金和对冲基金相信,一只股票有望实现长期增长。
Risk and Volatility
风险和波动性
Advaxis has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500.
Advaxis的贝塔系数为2.22,这意味着其股价的波动性比标准普尔500指数高122%。相比之下,Milest PharmPharmticals的贝塔系数为2.77,这意味着其股价的波动性比标准普尔500指数高177%。
Summary
摘要
Milestone Pharmaceuticals beats Advaxis on 8 of the 12 factors compared between the two stocks.
在两只股票之间的12个因素中,里程碑制药公司有8个因素超过了Advaxis。
About Advaxis
关于Advaxis
(Get Rating)
(获取评级)
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Advaxis,Inc.是一家临床阶段的生物技术公司,专注于在美国发现、开发和商业化专有的单核细胞增生性李斯特菌(LM)技术抗原递送产品。该公司正在开发ADXS-PSA,这是用于治疗转移性前列腺癌的第二阶段临床试验;ADXS-503,用于治疗非小细胞肺癌;以及ADXS-504,用于治疗前列腺癌。它还在进行以下领域的LM技术免疫疗法的临床研究:疾病热点/现成的新抗原导向疗法;人乳头瘤病毒相关癌症;以及前列腺癌。该公司与默克公司、OS Treateuies公司、Aratana治疗公司、Biocon有限公司、Global BioPharma Inc.、Knight Treateutics Inc.以及其他公司建立了合作和伙伴关系。Advaxis,Inc.成立于2002年,总部设在新泽西州的蒙茅斯路口。
About Milestone Pharmaceuticals
关于迈尔斯顿制药公司
(Get Rating)
(获取评级)
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
里程碑制药公司是一家生物制药公司,专注于心血管药物的开发和商业化。该公司正在开发新型通道阻滞剂依曲帕米,该药在美国和加拿大处于治疗阵发性室上性心动过速的第三阶段临床试验,以及治疗房颤和快速心室率的第二阶段临床试验。它与吉星制药公司签署了一项许可和合作协议,以开发和商业化用于人类的依曲帕米预防和治疗用途。该公司成立于2003年,总部设在加拿大的Montréal。
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Advaxis Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Advaxis和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧